Skip to main content
    I

    Immix Biopharma Inc (IMMX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $7.48
    -0.36 (-4.59%)

    Market Cap: $657.09M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Immix Biopharma Inc (IMMX) Financials: Revenue, Profit and Cash Flow

    Updated Nov 12, 2026. Financial statements from company filings, amounts in US dollars.

    Immix Biopharma reported revenue of $0 for the fiscal year ended Dec 31, 2025. That year, net income was -$29.44M, operating cash flow was -$23.93M and free cash flow was -$24.66M. The quarter ended Sep 30, 2026 had revenue of $0 and net income of -$13.93M.

    Revenue and Margins

    The company reported no revenue in the fiscal year ended Dec 2025, with an operating loss of $29.96M.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$0N/AN/AN/AN/A
    Dec 2024$0N/AN/AN/AN/A
    Dec 2023$0N/AN/AN/AN/A
    Dec 2022$0N/AN/AN/AN/A
    Dec 2021$0N/AN/AN/AN/A
    Dec 2020$0N/AN/AN/AN/A
    Dec 2019$0N/AN/AN/AN/A
    Annual, fiscal years ended Dec 2019 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Sep 2026, the net loss widened from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
    Cost of revenue$0$0$0$0$0$0$1.08K
    Gross profit$0$0$0$0$0$0-$1.08K
    Research and development$16.26M$11.29M$8.74M$4.20M$126.53K$248.15K$583.16K
    Operating income-$29.96M-$22.67M-$16.14M-$8.22M-$1.35M-$453.85K-$842.50K
    Net income-$29.44M-$21.70M-$15.60M-$8.23M-$24.38M-$1.15M-$972.81K
    EBITDA-$29.59M-$22.56M-$16.14M-$8.22MN/AN/A-$841.42K
    Fiscal years ended Dec 2019 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$0$0$0$0$0$0$0$96.29K$0$0$0$4.78K
    Gross profit$0$0$0-$90.63K$0$0$0$48.15K$0$0$0$1.71K
    Operating income-$15.95M-$12.46M-$10.80M-$10.89M-$7.66M-$6.72M-$4.68M-$4.99M-$7.39M-$4.70M-$5.59M-$5.38M
    Net income-$13.93M-$11.56M-$10.09M-$10.69M-$7.59M-$6.62M-$4.54M-$4.81M-$7.15M-$4.41M-$5.33M-$5.16M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded short-term debt of $139.34K by $93.79M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
    Total assets$104.84M$22.95M$19.93M$14.91M$18.19M$539.60K$942.94K
    Current assets$101.24M$20.20M$19.79M$14.90M$18.19M$532.24K$933.26K
    Cash and equivalents$93.93M$17.68M$17.51M$13.44M$17.64M$391.09K$734.01K
    Total liabilities$11.04M$9.70M$3.72M$1.75M$202.04K$5.27M$4.59M
    Short-term debt$139.34K$65.22KN/AN/A$50.00K$4.10M$4.10M
    Shareholder equity$93.80M$13.25M$16.41M$13.16M$17.99M-$4.73M-$3.65M
    Fiscal years ended Dec 2019 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$345.95M$239.11M$95.82M$104.84M$20.08M$15.64M$19.89M$22.95M$25.14M$28.84M$34.35M$19.93M
    Total liabilities$10.89M$10.19M$11.45M$11.04M$11.82M$10.98M$10.30M$9.70M$7.59M$4.94M$6.72M$3.72M
    Cash and equivalents$320.32M$225.49M$79.25M$93.93M$15.95M$11.64M$15.92M$17.68M$19.69M$23.98M$29.32M$17.51M
    Shareholder equity$335.06M$228.92M$84.36M$93.80M$8.26M$4.65M$9.59M$13.25M$17.55M$23.89M$27.92M$16.41M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
    Operating cash flow-$23.93M-$14.60M-$11.37M-$7.41M-$1.59M-$404.69K-$790.03K
    Capital expenditures$732.92K$1.18M$52.09K$0$802$0$7.31K
    Free cash flow-$24.66M-$15.77M-$11.42M-$7.41M-$1.59M-$404.69K-$797.34K
    Share repurchases$137.00K$0$234.62K$106.69K$0N/AN/A
    Investing cash flow-$7.21M-$1.18M-$52.09K$0-$802$0-$7.31K
    Financing cash flow$107.39M$15.95M$15.46M$3.23M$18.85M$0$1.05M
    Fiscal years ended Dec 2019 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$12.31M-$11.74M-$9.83M-$11.03M-$5.91M-$5.31M-$1.69M-$1.48M-$4.04M-$5.26M-$3.83M-$2.68M
    Capital expenditures$121.24K$21.04K$32.49K$165.13K$372.46K$127.63K$67.71K$507.15K$271.54K$97.07K$301.91K$13.18K
    Free cash flow-$12.43M-$11.76M-$9.86M-$11.19M-$6.28M-$5.44M-$1.75M-$1.98M-$4.31M-$5.35M-$4.13M-$2.69M
    Last 12 quarters

    Frequently Asked Questions About IMMX

    What is Immix Biopharma's annual revenue?

    Immix Biopharma reported revenue of $0 for the fiscal year ended Dec 31, 2025.

    Is Immix Biopharma profitable?

    No. Immix Biopharma reported net income of -$29.44M for the fiscal year ended Dec 31, 2025.

    How much free cash flow does IMMX generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$23.93M minus capital expenditures of $732.92K produced free cash flow of -$24.66M.

    How much debt does Immix Biopharma have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of $139.34K and cash and equivalents of $93.93M.